Wave Life Sciences Ltd.
NASDAQ · WVE·Cambridge, MA·Small-cap·Phase 2
Oligonucleotide platform company developing stereopure RNA-editing, GalNAc-siRNA, and exon-skipping antisense therapies. Lead clinical assets include WVE-006 (the first RNA-editing program in a clinical trial, in alpha-1 antitrypsin deficiency), WVE-N531 (DMD exon 53), and WVE-007 (INHBE GalNAc-siRNA for obesity), with a partnered Huntington's disease allele-selective program advancing alongside.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Wave Life Sciences Corporate Presentation | Corporate overview | April 28, 2026 | 51 |